Companies /Healthcare

Abbvie Inc

NYSE: ABBV Drug Manufacturers - General
$256.37
▼ $3.84 (−1.48%) today
Markets closed · 6:22pm ET

Q2 2025 Earnings

Reported Jul 31, 2025, 7:48am ET · SEC source
$2.97
Beat +2.14%
EPS · est. $2.91
$15.4B
Beat +2.61%
Revenue · est. $15.0B
+10.8%
Beating market
ABBV vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−2%0+2%Jul 31Aug 1report 7:48am ETearnings−3.0%+0.5%
−2%0+2%Jul 31Aug 1earnings−3.0%+0.5%
ABBV +0.5%S&P 500 −3.0%
−4%−2%0+2%Jul 31Aug 1report 7:48am ETearnings−3.8%+0.5%
−4%−2%0+2%Jul 31Aug 1earnings−3.8%+0.5%
ABBV +0.5%NASDAQ −3.8%
−3%0+3%Jul 30Aug 8report 7:48am ETearnings−0.8%+1.9%
−3%0+3%Jul 30Aug 8earnings−0.8%+1.9%
ABBV +1.9%S&P 500 −0.8%
−3%0+3%Jul 30Aug 8report 7:48am ETearnings−0.6%+1.9%
−3%0+3%Jul 30Aug 8earnings−0.6%+1.9%
ABBV +1.9%NASDAQ −0.6%
−0.15%
Day of report
+3.28%
Next session
+5.21%
One week
+12.12%
30 days

S&P 500 over the same 30 days: +1.30%.

Did ABBV Beat Earnings? Q2 2025 Results

AbbVie posted a confident second quarter for 2025, with adjusted diluted EPS of $2.97 edging past the $2.91 consensus by 2.14% and revenues of $15.42 billion climbing 6.7% year-over-year to clear analyst estimates by 2.61%, as the company's next-generation immunology franchise continued to carry the growth story. Skyrizi was the headline performer, surging 62.2% to $4.42 billion, while Rinvoq added 41.8% to reach $2.03 billion, collectively absorbing the ongoing biosimilar pressure on Humira, whose revenues fell 58.1% to $1.18 billion. Neuroscience added further momentum, with the migraine portfolio delivering outsized contributions from Ubrelvy and Qulipta. GAAP earnings were weighed by $2.79 billion in contingent consideration fair-value adjustments, a dynamic that has drawn scrutiny across the broader pharma sector as <a href="https://247wallst.com/investing/2025/07/17/live-abbott-labs-nyse-abt-q2-earnings-updates/">deal-related accounting headwinds</a> continue to cloud reported results for large-cap names. Looking ahead, AbbVie raised its full-year 2025 adjusted diluted EPS guidance to $11.88 to $12.08, up from $11.67 to $11.87, signaling sustained confidence in its immunology-led growth trajectory.

Key Takeaways
  • Skyrizi revenue growth of 62.2% year-over-year
  • Rinvoq revenue growth of 41.8% year-over-year
  • Neuroscience portfolio growth of 24.2% led by migraine therapies Ubrelvy and Qulipta
  • Adjusted operating margin of 44.3%
  • Lower adjusted tax rate of 16.2% vs 18.8% in prior year

“AbbVie delivered another outstanding quarter with strong performance from our diversified growth platform. We also made meaningful pipeline progress with several regulatory approvals, encouraging clinical data and strategic investments in promising external innovation.”

AbbVie CEO, on the earnings call

Forward Guidance & Outlook

AbbVie raised its full-year 2025 adjusted diluted EPS guidance range from $11.67 - $11.87 to $11.88 - $12.08, which includes an unfavorable impact of $0.55 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter. The guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond Q2 2025, as both cannot be reliably forecasted.

ABBV YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$0$5.0B$10.0B$15.0B$14.5B$15.4BRevenue$10.3B$11.1BGross Profit$4.0B$4.9BOperating Income$1.4B$938.0MNet Income
$0$5.0B$10.0B$15.0BRevenueGross ProfitOperating IncomeNet Income

ABBV Revenue by Segment

Immunology$7.6B+9.5%
Skyrizi$4.4B+62.2%
Neuroscience$2.7B+24.2%
Rinvoq$2.0B+41.8%
Oncology$1.7B+2.6%
Aesthetics$1.3B−8.1%
Humira$1.2B−58.1%
Vraylar$900.0M+16.3%

ABBV Revenue by Geography

United States$11.8B+5.9%
Rest of World$3.7B+9.1%

Figures from SEC filings and company reports. Not investment advice.